Covaxin 65.2% effective against Delta variant

Hyderabad: Bharat Biotechs Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.

The company on Saturday said it concluded the final analysis of Covaxin efficacy from Phase 3 trials.

The efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19 cases while safety analysis shows adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent feeling serious adverse events.

The efficacy data demonstrates 63.6 per cent protection against asymptomatic COVID-19, a release from the city-based vaccine maker said.

Phase 3 clinical trials of the vaccine was an event-driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the second dose, conducted at 25 sites across India.

The whole virion inactivated vaccine against SARS-CoV2, was developed in partnership with the Indian Council of Medical Research and the National Institute of Virology in Pune.

The Phase 3 trials were conducted between November 16, 2020 and January 7, 2021 with 25,798 participants who were randomised to BBV152 or placebo groups.

The preprint data of COVAXIN efficacy has not been certified by peer-review, according to Medrxiv in which the data was published.